中国药房2017，Vol.28Issue(33)：4661-4663,3.DOI:10.6039/j.issn.1001-0408.2017.33.15
达比加群酯与华法林用于非瓣膜性心房颤动患者抗凝的有效性与安全性比较
Comparison of Anticoagulant Efficacy and Safety of Dabigatran Etexilate and Warfarin in the Treatment of Non-valvular Atrial Fibrillation
郭红雨 1段永珂 2洪岩 1程冠昌1
作者信息
- 1. 河南大学淮河医院心内科,河南开封 475000
- 2. 开封大学医学院,河南开封 475000
- 折叠
摘要
Abstract
OBJECTIVE:To compare anticoagulant efficacy and safety of dabigatran etexilate and warfarin in the treatment of non-valvular atrial fibrillation(NVAF). METHODS:In retrospective analysis,360 NVAF patients were divided into control group (180 cases)and observation group(180 cases)according to therapy plan. Control group was given Warfarin sodium tablet with ini-tial dose of 2.5 mg orally,once a day,adjusted dosage according to INR. Observation group was given Dabigatran etexilate cap-sule 150 mg with warm water,twice a day,during or after meal. The levels of ALT,AST and INR,the occurrence of ADR were observed in 2 groups before treatment and 1,3 month after treatment. RESULTS:There was no statistical significance in the levels of ALT or AST between 2 groups before and after treatment (P>0.05). Before treatment,there was no statistical significance in INR between 2 groups (P>0.05),1,3 months after treatment,INR in control group was significantly higher than before treat-ment,with statistical significance(P<0.05);there was no statistical significance in the INR of observation group before and after treatment(P>0.05);but INR of 2 groups ranged were in normal range. There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Anticoagnlant efficacy of dabigatran etexilate is significantly better than war-farin for NVAF. Both have similar safety.关键词
达比加群酯/华法林/非瓣膜性心房颤动/抗凝/有效性/安全性Key words
Dabigatran etexilate/Warfarin/Non-valvular atrial fibrillation/Anticoagnlant/Efficacy/Safety分类
医药卫生引用本文复制引用
郭红雨,段永珂,洪岩,程冠昌..达比加群酯与华法林用于非瓣膜性心房颤动患者抗凝的有效性与安全性比较[J].中国药房,2017,28(33):4661-4663,3.
